311 related articles for article (PubMed ID: 17914026)
1. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome.
Fang CJ; Fremeaux-Bacchi V; Liszewski MK; Pianetti G; Noris M; Goodship TH; Atkinson JP
Blood; 2008 Jan; 111(2):624-32. PubMed ID: 17914026
[TBL] [Abstract][Full Text] [Related]
2. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
[TBL] [Abstract][Full Text] [Related]
3. Atypical hemolytic uremic syndrome.
Loirat C; Frémeaux-Bacchi V
Orphanet J Rare Dis; 2011 Sep; 6():60. PubMed ID: 21902819
[TBL] [Abstract][Full Text] [Related]
4. Mutations in CD46, a complement regulatory protein, predispose to atypical HUS.
Goodship TH; Liszewski MK; Kemp EJ; Richards A; Atkinson JP
Trends Mol Med; 2004 May; 10(5):226-31. PubMed ID: 15121049
[TBL] [Abstract][Full Text] [Related]
5. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
Noris M; Caprioli J; Bresin E; Mossali C; Pianetti G; Gamba S; Daina E; Fenili C; Castelletti F; Sorosina A; Piras R; Donadelli R; Maranta R; van der Meer I; Conway EM; Zipfel PF; Goodship TH; Remuzzi G
Clin J Am Soc Nephrol; 2010 Oct; 5(10):1844-59. PubMed ID: 20595690
[TBL] [Abstract][Full Text] [Related]
6. Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.
Alberti M; Valoti E; Piras R; Bresin E; Galbusera M; Tripodo C; Thaiss F; Remuzzi G; Noris M
Am J Transplant; 2013 Aug; 13(8):2201-6. PubMed ID: 23731345
[TBL] [Abstract][Full Text] [Related]
7. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
[TBL] [Abstract][Full Text] [Related]
8. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].
Frémeaux-Bacchi V; Fakhouri F; Roumenina L; Dragon-Durey MA; Loirat C
Rev Med Interne; 2011 Apr; 32(4):232-40. PubMed ID: 21376430
[TBL] [Abstract][Full Text] [Related]
9. Complement activation in diseases presenting with thrombotic microangiopathy.
Meri S
Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
[TBL] [Abstract][Full Text] [Related]
10. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
11. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
[TBL] [Abstract][Full Text] [Related]
12. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.
Roumenina LT; Frimat M; Miller EC; Provot F; Dragon-Durey MA; Bordereau P; Bigot S; Hue C; Satchell SC; Mathieson PW; Mousson C; Noel C; Sautes-Fridman C; Halbwachs-Mecarelli L; Atkinson JP; Lionet A; Fremeaux-Bacchi V
Blood; 2012 May; 119(18):4182-91. PubMed ID: 22246034
[TBL] [Abstract][Full Text] [Related]
13. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.
Caprioli J; Noris M; Brioschi S; Pianetti G; Castelletti F; Bettinaglio P; Mele C; Bresin E; Cassis L; Gamba S; Porrati F; Bucchioni S; Monteferrante G; Fang CJ; Liszewski MK; Kavanagh D; Atkinson JP; Remuzzi G;
Blood; 2006 Aug; 108(4):1267-79. PubMed ID: 16621965
[TBL] [Abstract][Full Text] [Related]
14. Rapid recovery of membrane cofactor protein (MCP; CD46) associated atypical haemolytic uraemic syndrome with plasma exchange.
Reid VL; Mullan A; Erwig LP
BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24005975
[TBL] [Abstract][Full Text] [Related]
15. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
Kavanagh D; Burgess R; Spitzer D; Richards A; Diaz-Torres ML; Goodship JA; Hourcade DE; Atkinson JP; Goodship TH
Mol Immunol; 2007 May; 44(12):3162-7. PubMed ID: 17368771
[TBL] [Abstract][Full Text] [Related]
16. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome.
Maga TK; Nishimura CJ; Weaver AE; Frees KL; Smith RJ
Hum Mutat; 2010 Jun; 31(6):E1445-60. PubMed ID: 20513133
[TBL] [Abstract][Full Text] [Related]
17. Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP.
Provaznikova D; Rittich S; Malina M; Seeman T; Marinov I; Riedl M; Hrachovinova I
Pediatr Nephrol; 2012 Jan; 27(1):73-81. PubMed ID: 21706448
[TBL] [Abstract][Full Text] [Related]
18. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome.
Fan X; Yoshida Y; Honda S; Matsumoto M; Sawada Y; Hattori M; Hisanaga S; Hiwa R; Nakamura F; Tomomori M; Miyagawa S; Fujimaru R; Yamada H; Sawai T; Ikeda Y; Iwata N; Uemura O; Matsukuma E; Aizawa Y; Harada H; Wada H; Ishikawa E; Ashida A; Nangaku M; Miyata T; Fujimura Y
Mol Immunol; 2013 Jun; 54(2):238-46. PubMed ID: 23314101
[TBL] [Abstract][Full Text] [Related]
19. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity.
Blom AM; Bergström F; Edey M; Diaz-Torres M; Kavanagh D; Lampe A; Goodship JA; Strain L; Moghal N; McHugh M; Inward C; Tomson C; Frémeaux-Bacchi V; Villoutreix BO; Goodship TH
J Immunol; 2008 May; 180(9):6385-91. PubMed ID: 18424762
[TBL] [Abstract][Full Text] [Related]
20. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.
Frémeaux-Bacchi V; Miller EC; Liszewski MK; Strain L; Blouin J; Brown AL; Moghal N; Kaplan BS; Weiss RA; Lhotta K; Kapur G; Mattoo T; Nivet H; Wong W; Gie S; Hurault de Ligny B; Fischbach M; Gupta R; Hauhart R; Meunier V; Loirat C; Dragon-Durey MA; Fridman WH; Janssen BJ; Goodship TH; Atkinson JP
Blood; 2008 Dec; 112(13):4948-52. PubMed ID: 18796626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
